Somatic pathogenic variants can occur additionally to NF2 gene variants such as in AKT1 (e.g. AKT1E17K variant) which highlights the importance of tumor genome analysis prior to a targeted therapy [7]. This evidence concerns the gene NF2 and neoplasm.